Skip to main content

Shares of cancer biotech Cyteir down after $133M IPO

Cyteir Therapeutics, an early-stage oncology startup, raised $133 million on its first day of trading on Friday — but its share prices have fallen after an initial rise.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.